← Leaderboards
Michael W. Otto
Massachusetts General Hospital
$8,919,189
Attributed
$10,635,365
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,635,365 · 11
By mechanism
R01$5,747,935 · 3
R21$2,417,064 · 5
R33$1,690,491 · 1
R34$621,887 · 1
R25$157,988 · 1
Top collaborators
- Kathleen M. Kantak5 shared
- Jasper Smits3 shared
- Michael J Zvolensky3 shared
- Stacey N. Doan2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Suzanne McCluskey$4,542,101
- Mark H Pollack$7,343,315
- Jean A Frazier$5,312,164
- Karmel Choi$1,733,505
- Josephine H Li$762,683
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseAnxietySeveritiesExposure ToDesignProtocols DocumentationImpairmentLinkAnxiety DisordersFrightFollow-UpSamplingProceduresClinical ResearchCognitive TherapyProgramsTreatment StrategyMediatingPanic DisorderBasic ScienceAreaOutpatientsSubstance Use DisorderInvestigation
Grant awards (40)
2/2-CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy$477,568
R01 · FY2025 · MH · contact PI
2/2-CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy$565,351
R01 · FY2024 · MH · contact PI
2/2-CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy$565,351
R01 · FY2023 · MH · contact PI
Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse$542,238
R33 · FY2023 · DA · contact PI
2/2-CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy$596,287
R01 · FY2022 · MH · contact PI
Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse$549,328
R33 · FY2022 · DA · contact PI
Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse$598,925
R33 · FY2021 · DA · contact PI
Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse$225,977
R21 · FY2019 · DA · contact PI
Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation$209,810
R21 · FY2019 · DA · contact PI
Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation$8,167
R21 · FY2019 · DA · contact PI
Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation$257,458
R21 · FY2018 · DA · contact PI
Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse$227,773
R21 · FY2018 · DA · contact PI
Rescuing Cognitive and Emotional Regulatory Processes to Aid Smoking Prevention$201,279
R21 · FY2017 · DA · contact PI
Rescuing Cognitive and Emotional Regulatory Processes to Aid Smoking Prevention$257,649
R21 · FY2016 · DA · contact PI
Improving Therapeutic Learning in Depression: Proof of Concept$205,100
R21 · FY2015 · MH · contact PI
Enhancing Panic and Smoking Reduction Treatment with D-Cycloserine$199,549
R34 · FY2015 · DA
Improving Therapeutic Learning in Depression: Proof of Concept$246,647
R21 · FY2014 · MH · contact PI
Enhancing Panic and Smoking Reduction Treatment with D-Cycloserine$202,588
R34 · FY2014 · DA
Enhancing Panic and Smoking Reduction Treatment with D-Cycloserine$219,750
R34 · FY2013 · DA
1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder$217,181
R01 · FY2012 · MH · contact PI
Excellence In Training: The Center for Anxiety and Related Disorders at BU$30,879
R25 · FY2012 · MH · contact PI
1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder$253,378
R01 · FY2011 · MH · contact PI
Excellence In Training: The Center for Anxiety and Related Disorders at BU$31,386
R25 · FY2011 · MH · contact PI
1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder$255,938
R01 · FY2010 · MH · contact PI
Excellence In Training: The Center for Anxiety and Related Disorders at BU$31,335
R25 · FY2010 · MH · contact PI
1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder$255,938
R01 · FY2009 · MH · contact PI
Excellence In Training: The Center for Anxiety and Related Disorders at BU$31,992
R25 · FY2009 · MH · contact PI
Stress, Distress Intolerance, and Drug Dependence$419,770
R01 · FY2008 · DA · contact PI
1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder$219,375
R01 · FY2008 · MH · contact PI
Excellence In Training: The Center for Anxiety and Related Disorders at BU$32,396
R25 · FY2008 · MH · contact PI
Stress, Distress Intolerance, and Drug Dependence$482,640
R01 · FY2007 · DA · contact PI
Stress, Distress Intolerance, and Drug Dependence$473,598
R01 · FY2006 · DA · contact PI
Context Effects in De Novo Fear Conditioning in Humans$183,109
R21 · FY2006 · MH · contact PI
Stress, Distress Intolerance, and Drug Dependence$60,608
R01 · FY2006 · DA · contact PI
Stress, Distress Intolerance, and Drug Dependence$43,440
R01 · FY2006 · DA · contact PI
Stress, Distress Intolerance, and Drug Dependence$430,065
R01 · FY2005 · DA
Context Effects in De Novo Fear Conditioning in Humans$132,095
R21 · FY2005 · MH
Stress, Distress Intolerance, and Drug Dependence$431,447
R01 · FY2004 · DA
Context Effects in De Novo Fear Conditioning in Humans$206,580
R21 · FY2004 · MH
Context Effects in De Novo Fear Conditioning in Humans$55,420
R21 · FY2004 · MH